VivoSeq
Respiratory

Chronic Cough

41

Pipeline Programs↗

11

Active Trials↗

25

Companies Involved↗

Chronic Cough is a moderately active landscape with 41 programs across 25 companies. The most active players are GSK, Merck & Co., Bayer. 7 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

15/100

Mech. Concentration

17/100

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

3 programs

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2Bayer logo

Bayer

2 programs

Phase 2B

Beijing Tide Pharmaceutical Co., Ltd

1 program

Phase 2Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

1 program

Phase 2V

Vyne Therapeutics Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Adenosine Triphosphate

Egyptian International Pharmaceutical Industries Co

Iron Sulphate

Pierre Fabre Pharma GmbH

Budesonide Novolizer

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Standard PPI

Yonsei University

High-Dose PPI

Yonsei University

Phase 12

Triamcinolone Acetonide

Bausch Health Americas, Inc.

NOC-100

Nocion Therapeutics

Phase 223

Amitriptyline

AstraZeneca

Midazolam

Conrado Roberto Hoffmann Filho

Duloxetine

Alnylam Pharmaceuticals

Gefapixant

Merck & Co.

SCH 56592

Merck & Co.

Phase 34

Indomethacin

Life Extension Foundation Inc.

Omeprazole

Dexcel Pharma Technologies Ltd.

Proton Pump Inhibitor

AVM Biotechnology Inc

Ag1321001(drug)

Ahn-Gook Pharmaceuticals Co.,Ltd

Approved7

Mepolizumab

Glaxo Dba Glaxosmithkline

Esomeprazole

Dexcel Pharma Technologies Ltd.

Capsaicin

Averitas Pharma, Inc.

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Montelukast

Organon and Co

Analysis

Modality Breakdown

96%

Small molecule

47 of 49 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody12%Cell therapy12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 49 pipeline programs.

Analysis

Trial Status

62

clinical trials

Completed41 · 66%
Unknown status6 · 10%
Recruiting6 · 10%
Not yet recruiting4 · 6%
Terminated3 · 5%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

62 trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Recruiting·—·Phase 3·NCT05600777·975 enrolled
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
Recruiting·NNocion Therapeutics·Phase 2·NCT06504446·455 enrolled
Efficacy of Intramuscular Steroid Injection for Chronic Cough.
Recruiting·MMedical University of South Carolina·Phase 1·NCT06634823·40 enrolled
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
Recruiting·MMayo Clinic·Phase 2·NCT05110144·50 enrolled
Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough
Recruiting·—·Phase 1·NCT05813223·31 enrolled
Does Chronic Cough Lead to Injury and Remodelling of the Lower Airways?
Recruiting·MMedical University of Warsaw·N/A·NCT07659860·40 enrolled
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Active, not recruiting·—·Phase 3·NCT05599191·825 enrolled
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
Not yet recruiting·MMcMaster University·Phase 4·NCT07288528·124 enrolled
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
Not yet recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 2·NCT07483489·180 enrolled
A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
Not yet recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 2·NCT06246565·276 enrolled
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Not yet recruiting·UUniversity of Montana·Phase 2·NCT06960759·135 enrolled
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT04193202·419 enrolled
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough
Completed·Roche logoRoche·Phase 2·NCT05660850·49 enrolled
A Dose Escalation Study of Bradanicline in Refractory Chronic Cough
Completed·AAttenua, Inc.·Phase 2·NCT03622216·46 enrolled
The Utility of feNO in the Differential Diagnosis of Chronic Cough
Completed·HHull University Teaching Hospitals NHS Trust·Phase 4·NCT02479074·49 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)